Inflammation  >>  Arlansa (narlaprevir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arlansa (narlaprevir) / Merck (MSD)
NEXT-1, NCT00797745: A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

Checkmark AASLD 2011
Oct 2011 - Oct 2011: AASLD 2011
Completed
2
111
US
peginterferon alfa 2b, PegIntron, ribavirin, REBETOL, SCH 900518, ritonavir, Norvir
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
07/09
09/10
NCT03485846: Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Completed
2
105
RoW
Narlaprevir, Arlansa, Ritonavir, Norvir, Daclatasvir, Daklinza
R-Pharm, Almedis
Chronic Hepatitis C Genotype 1b
08/18
11/18
NCT04246723: Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Completed
2
85
RoW
Narlaprevir, Ritonavir, Sofosbuvir
R-Pharm, Almedis, Scientific Center EFiS, ChromSystemsLab
Chronic Hepatitis c Genotype 1
04/20
08/20

Download Options